




**Fig. S1. The *cdh15* transgenic muscle promoter is expressed in developing somites during early and mid-somitogenesis.** (A-D) Whole-mount RNA *in situ* hybridization was performed on 10 somite (A,C) and 16 somite (B,D) *cdh15:GFP* transgenic embryos using *GFP* anti-sense (C,D) RNA probes or sense (A,B) control probes. Flat-mounted embryos are depicted, with anterior on the left. Significant background staining is seen in the anterior embryo in sense controls. High levels of somite-specific staining are seen only in antisense probe-treated embryos.



**Fig. S2. Gene expression of muscle markers in sorted cell populations from *cdh15:gfp* and *mylz2:mCherry* fish, quantified by QPCR.** Cells from three adult *cdh15:gfp* and three adult *mylz2:mCherry* fish were double-sorted for GFP or mCherry positivity, respectively, to relative purity (>90%). RNA was isolated and QPCR was performed to quantify expression of muscle genes in the fluorophore-positive populations. There was a significant increase ( $P=0.007$ , Student's *t*-test) in *mylz2* expression in mCherry-positive cells from *mylz2:mCherry* fish, and a non-significant increase in *cpvl*, a marker of muscle differentiation. There was a non-significant increase in *myod1* and *myog* expression in GFP-positive cells from *cdh15:gfp* fish. Expression of *myf5*, *cdh15*, *pax7*, *myog* and *cpvl* could not be evaluated in one *cdh15:gfp* fish ('cdh15-1') owing to insufficient RNA. The average of three experimental replicates is depicted per sample. Error bars represent s.e.m.




**Fig. S3. *rag2* transgenic muscle promoter recapitulates endogenous expression patterns during development.** (A-H) Whole-mount RNA *in situ* hybridization was performed on endogenous *rag2* transcript in AB strain wild-type embryos (A-D), or on *GFP* transcript in transgenic embryos (E-H). (A,E) 10 somite stage. (B,F) 15 somite stage. (C,G) 24 hours post fertilization (hpf). (D,H) 5 days post fertilization (dpf). Anterior is on the left. Arrowheads denote the location of the thymus in 5 dpf larvae.



**Fig. S4. Muscle promoter-driven *KRAS*<sup>G12D</sup> expression in mosaic transgenic embryos and larvae are largely consistent with endogenous expression patterns. (A-VV)** Whole-mount RNA *in situ* hybridization was performed using *KRAS* anti-sense RNA probes (E-P,U-FF, KK-VV) or *KRAS* sense controls (A-D,Q-T, GG-JJ) on embryos or larvae that had been injected at the one-cell stage with *rag2*:*KRAS*<sup>G12D</sup> (A-P), *cdh15*:*KRAS*<sup>G12D</sup> (Q-FF), or *mylz2*:*KRAS*<sup>G12D</sup> (GG-VV) vectors. For each time point, one representative sense control staining and three representative anti-sense probe stainings are depicted. (A,E,I,M,Q,U,Y,CC,GG, KK,OO,SS) 10 somite stage. (B,F,J,N,R,V,Z,DD,HH,LL,PP,TT) 16 somite stage. (C,G,K,O,S,W,AA,EE,II,MM,QQ,UU) 24 hpf. (D,H,L,P,T,X,BB,FF, JJ,NN,RR,VV) 5 dpf. Black arrowheads indicate areas of muscle staining at 5 dpf. Unfilled arrowhead indicates area in one *rag2* embryo (1 out of 71 embryos) that displayed a population of cells with anti-sense staining. Arrows represent positive muscle fibers in a 10 somite *mylz2* embryo.





**Fig. S5. *rag2:KRAS<sup>G12D</sup>*, *cdh15:KRAS<sup>G12D</sup>* and *mylz2:KRAS<sup>G12D</sup>* tumors express phospho-S6 ribosomal protein (pS6RP) at similar levels.** (A-N) H&E staining (A-G) and immunohistochemistry staining of S6RP (H-N) of two representative *rag2* (A,B,H,I), *cdh15* (C,D,J,K) and *mylz2* (E,F,L,M) tumors, or one normal muscle (G,N) section. Scale bars: 50  $\mu$ m. All images are at the same magnification.

**Table S1. Up- and downregulated gene lists for the following comparisons.** Wild-type versus *cdh15* tumors (sheet A), wild-type versus *mylz2* tumors (sheet B), wild-type versus *rag2* tumors (sheet C), *cdh15* versus *mylz2* tumors (sheet D), *cdh15* versus *rag2* tumors (sheet E) and *mylz2* versus *rag2* tumors (sheet F). Venn diagrams depicting the overlap of dysregulated genes in tumors compared to wild type are shown in sheet G. GSEA plots showing enrichment of *mylz2* signature compared with *rag2* (sheet H) or *cdh15* (sheet I) in human well-differentiated (WD) RMS. Heatmaps of the GSEA results are also included.

[Download Table S1](#)

**Table S2. GFP-positive cells are enriched for tumor-propagating capability in secondary transplantations of *rag2* and *cdh15* tumors.** Results are depicted as number of fish showing tumor engraftment out of number of total fish transplanted for each dilution.

tumor	cell population	# cells transplanted		
		1,000	100	10
<b>rag2</b>	<b>G+R-</b>	-	6 of 10	1 of 9
	<b>G+R+</b>	-	2 of 10	0 of 9
	<b>G-R+</b>	0 of 8	-	-
	<b>G-R-</b>	0 of 10	-	-
<b>cdh15</b>	<b>G+R-</b>	-	-	2 of 16
	<b>G+R+</b>	-	4 of 7	1 of 14
	<b>G-R+</b>	-	0 of 14	-
	<b>G-R-</b>	0 of 13	-	-

**Table S3. Oligonucleotide primer sequences**

<b>Primers for cloning promoter elements</b>	
cdh15-XhoI-F	5'-AATTCCTCGAGTCATCTTGTGTGCAACTACTGTGTCG-3'
cdh15-BamHI-R	5'-GGAATTGGATCCCCTCAATGACCACAGTAAACCACTGC-3'
mylz2-XhoI-F	5'-AATTCCTCGACCTCGAGATTCGCCACAGAGGAATGAGCCACCA-3'
mylz2-BamHI-R	5'-GGAATTGGATCCGTCGAGACGGTATGTGTGAAGTCT-3'

<b>Primers for generating in situ hybridization probes</b>	
GFP-T7-F	5'-TTCCGTAATACGACTCACTATAGGGGAAGGTGATGCAACATACGG-3'
GFP-SP6-R	5'-TTCCGATTTAGGTGACACTATAGAACCATGTGGTCTCTCTTTTCG-3'
mCherry-T7-F	5'-TTCCGTAATACGACTCACTATAGGGACATGGCCATCATCAAGGAG-3'
mCherry-SP6-R	5'-TTCCGATTTAGGTGACACTATAGAAGTTCCACGATGGTGTAGTCC-3'
mylz2-T7-F	5'-TTCCGTAATACGACTCACTATAGGGTCATCAGCAAAGACGACCTTAGG-3'
mylz2-SP6-R	5'-TTCCGATTTAGGTGACACTATAGAATTACTCCTCCTTCTCCTCTCCGTG-3'
cdh15-T7-F	5'-TTCCGTAATACGACTCACTATAGGGAACAACTGATTGCGGAGGTTG-3'
cdh15-SP6-R	5'-TTCCGATTTAGGTGACACTATAGAATGTCTTCATCCAAGGCACTAAGC-3'
rag2-T7-F	5'-TTCCGTAATACGACTCACTATAGGGAGCTGTCTCCAGTCTCTACAT-3'
rag2-SP6-R	5'-TTCCGATTTAGGTGACACTATAGAAAGACTCCATATGGACTCCCACA-3'
hKRAS-SP6-F	5'-TTCCATTTAGGTGACACTATAGCTTGTGGTAGTTGGAGCTGA-3'
hKRAS-T7-R	5'-TTCCGTAATACGACTCACTATAGGGCACTAATGTATAGAAGGCATC-3'

<b>Primers for quantitative RT-PCR</b>	
EF1a-QRT-F	5'-CATCGAGAAGTTCGAGAAGGAAGC-3'
EF1a-QRT-R	5'-GTCAATGGTGATACCACGCTCAC-3'
hKRAS-QRT-F	5'-TTGATGGAGAAACCTGTCTCTTGG-3'
hKRAS-QRT-R	5'-CAAATACACAAAGAAAGCCCTCCC-3'
pax7b-QRT-F	5'-CAGTATTGACGGCATTCTGGGAG-3'
pax7b-QRT-R	5'-TCTCTGCTTTCTCTTGAGCGGC-3'
myf5-QRT-F	5'-CCAGACAGTCCAAACAACAGACC-3'
myf5-QRT-R	5'-TGAGCAAGCAGTGTGAGTAAGCG-3'
cdh15-QRT-F	5'-CTAAGGAAAGATGCACCCATTAC-3'
cdh15-QRT-R	5'-TCAGAGCTGTGTCGTATGGTGG-3'
myog-QRT-F	5'-GTGGACAGCATAACGGGAACAG-3'
myog-QRT-R	5'-TCTGAAGGTAACGGTGAGTCGG-3'
desmin-QRT-F	5'-CGAGATTGACTCTCTCAAGGGCAC-3'
desmin-QRT-R	5'-GGGCGATAGTGTCTGATAACCAC-3'
mylz2-QRT-F	5'-TTGACCACTCAGTGCAGAGGTTTC-3'
mylz2-QRT-R	5'-AACATTGCCAGCCACATCTGGG-3'
cpvl-QRT-F	5'-TTGGAGCTGACCCGGGCAAA-3'
cpvl-QRT-R	5'-CACCAGGAAGGGGACCCACC-3'